Published in Proc Natl Acad Sci U S A on July 07, 2008
Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA. Nat Mater (2009) 2.87
The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Annu Rev Clin Psychol (2009) 2.39
Microbicides: topical prevention against HIV. Cold Spring Harb Perspect Med (2012) 1.31
Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Antimicrob Agents Chemother (2011) 1.25
Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models. PLoS Med (2011) 1.10
Selection of a simian-human immunodeficiency virus strain resistant to a vaginal microbicide in macaques. J Virol (2009) 1.01
Candidate vaginal microbicides with activity against Chlamydia trachomatis and Neisseriagonorrhoeae. Int J Antimicrob Agents (2010) 0.99
HIV treatment as prevention: principles of good HIV epidemiology modelling for public health decision-making in all modes of prevention and evaluation. PLoS Med (2012) 0.99
Modelling the impact of antiretroviral therapy on the epidemic of HIV. Curr HIV Res (2011) 0.98
HIV transmission: time for translational studies to bridge the gap. Sci Transl Med (2011) 0.97
Who will Benefit from a Wide-Scale Introduction of Vaginal Microbicides in Developing Countries? Stat Commun Infect Dis (2010) 0.95
Modeling the gender-specific impact of vaginal microbicides on HIV transmission. J Theor Biol (2011) 0.94
Mapping the architecture of the HIV-1 Tat circuit: A decision-making circuit that lacks bistability and exploits stochastic noise. Methods (2010) 0.93
Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides. Antimicrob Agents Chemother (2011) 0.90
Beating the placebo in HIV prevention efficacy trials: the role of the minimal efficacy bound. J Acquir Immune Defic Syndr (2013) 0.90
Combination HIV prevention interventions: the potential of integrated behavioral and biomedical approaches. Curr HIV/AIDS Rep (2014) 0.86
Impact of Pill Sharing on Drug Resistance Due to a Wide-Scale Oral Prep Intervention in Generalized Epidemics. J AIDS Clin Res (2012) 0.86
Predicting the unpredictable real-world impact of ARV-based microbicides. Proc Natl Acad Sci U S A (2008) 0.85
In vitro surfactant structure-toxicity relationships: implications for surfactant use in sexually transmitted infection prophylaxis and contraception. PLoS One (2011) 0.84
Vaccines, virucides and drugs against HIV/AIDS: hopes and optimisms for the future. Open AIDS J (2009) 0.83
What do mathematical models tell us about the emergence and spread of drug-resistant HIV? Curr Opin HIV AIDS (2011) 0.82
Analytic review of modeling studies of ARV Based PrEP interventions reveals strong influence of drug-resistance assumptions on the population-level effectiveness. PLoS One (2013) 0.81
A perspective on progress and gaps in HIV prevention science. AIDS Res Hum Retroviruses (2012) 0.79
Intravaginal practices and microbicide acceptability in Papua New Guinea: implications for HIV prevention in a moderate-prevalence setting. BMC Res Notes (2012) 0.79
Potential impact of vaginal microbicides on HIV risk among women with primary heterosexual partners. J Assoc Nurses AIDS Care (2010) 0.79
Comparing the cost effectiveness of harm reduction strategies: a case study of the Ukraine. Cost Eff Resour Alloc (2014) 0.77
Mathematical insights in evaluating state dependent effectiveness of HIV prevention interventions. Bull Math Biol (2013) 0.77
Assessing the Public Health impact of HIV interventions: the critical role of demographics. J Acquir Immune Defic Syndr (2014) 0.77
How Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health Impact. PLoS One (2016) 0.75
Network effects of risk behavior change following prophylactic interventions. PLoS One (2013) 0.75
Impact of Population Recruitment on the HIV Epidemics and the Effectiveness of HIV Prevention Interventions. Bull Math Biol (2016) 0.75
Degradable bioadhesive nanoparticles for prolonged intravaginal delivery and retention of elvitegravir. Biomaterials (2017) 0.75
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol (2003) 5.29
Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science (2004) 3.95
High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci U S A (2008) 2.82
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS (2006) 2.77
HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol (2006) 2.72
Why consider vaginal drug administration? Fertil Steril (2004) 2.54
Public health. Regulatory challenges in microbicide development. Science (2004) 2.28
Pre-exposure prophylaxis for HIV infection: what if it works? Lancet (2007) 2.07
Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des (2004) 1.97
Protection of macaques from vaginal SHIV challenge by an orally delivered CCR5 inhibitor. Nat Med (2005) 1.92
The vagina as a route for systemic drug delivery. J Control Release (2005) 1.58
In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemother (2004) 1.54
Challenges to HIV prevention--seeking effective measures in the absence of a vaccine. N Engl J Med (2008) 1.53
Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother (2005) 1.48
A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine (2006) 1.48
Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J Antimicrob Chemother (2006) 1.31
HIV trial doomed by design, say critics. Nature (2007) 1.20
The epidemiological and control implications of HIV transmission probabilities within partnerships. Sex Transm Dis (2002) 1.17
Microbicides--aids to safer sex. Lancet (2004) 1.14
Absorption from the vagina. Drug Metab Rev (1983) 1.13
Intravaginal and intrarectal microbicides to prevent HIV infection. CMAJ (2005) 1.10
Novel HIV-1 reverse transcriptase inhibitors. Virus Res (2008) 1.09
Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol (2002) 1.02
Intravaginal gels as drug delivery systems. J Womens Health (Larchmt) (2004) 1.02
Systemic delivery of peptides and proteins across absorptive mucosae. Crit Rev Ther Drug Carrier Syst (1996) 1.00
Permeability of tritiated water through human cervical and vaginal tissue. J Pharm Sci (2004) 1.00
Drug delivery by the intravaginal route. Crit Rev Ther Drug Carrier Syst (2000) 0.99
Resistance issues with new nucleoside/nucleotide backbone options. J Acquir Immune Defic Syndr (2004) 0.92
Biosensor-based kinetic characterization of the interaction between HIV-1 reverse transcriptase and non-nucleoside inhibitors. J Med Chem (2006) 0.90
Comparative in vitro permeability of human vaginal, small intestinal and colonic mucosa. Int J Pharm (2003) 0.89
Microbicides: anti-HIV efficacy and ethics. Science (2004) 0.80
High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis (2007) 7.70
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med (2015) 4.26
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS (2003) 3.60
Designing equitable antiretroviral allocation strategies in resource-constrained countries. PLoS Med (2005) 2.84
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS (2006) 2.77
Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet (2002) 2.44
Evaluating the potential impact of vaginal microbicides to reduce the risk of acquiring HIV in female sex workers. AIDS (2005) 2.33
High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother (2006) 2.23
Whither or wither microbicides? Science (2008) 2.17
Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus. AIDS (2003) 2.11
The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults. Clin J Pain (2007) 2.08
Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother (2003) 2.04
Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression. J Virol (2005) 2.02
The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. J Virol (2009) 2.00
Characterization of a putative alpha-helix across the capsid-SP1 boundary that is critical for the multimerization of human immunodeficiency virus type 1 gag. J Virol (2002) 1.96
Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol (2011) 1.95
Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS (2008) 1.89
Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol (2002) 1.84
Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother (2002) 1.82
Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J Virol (2008) 1.79
Could disease-modifying HIV vaccines cause population-level perversity? Lancet Infect Dis (2004) 1.79
Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine? AIDS (2003) 1.78
Transmission clustering drives the onward spread of the HIV epidemic among men who have sex with men in Quebec. J Infect Dis (2011) 1.70
Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology (2013) 1.66
Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS (2004) 1.61
Is HIV-1 RNA dimerization a prerequisite for packaging? Yes, no, probably? Retrovirology (2004) 1.59
Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J Virol (2011) 1.58
RIG-I-mediated antiviral signaling is inhibited in HIV-1 infection by a protease-mediated sequestration of RIG-I. J Virol (2010) 1.55
Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antivir Ther (2003) 1.53
Predicting the epidemiological impact of antiretroviral allocation strategies in KwaZulu-Natal: the effect of the urban-rural divide. Proc Natl Acad Sci U S A (2006) 1.52
The role of surrogate markers in the clinical development of antiretroviral therapy: a model for early evaluation of targeted cancer drugs. Cancer Invest (2004) 1.50
Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol (2010) 1.46
Indinavir did not further increase mean triglyceride levels in HIV-infected patients treated with nucleoside reverse transcriptase inhibitors: an analysis of three randomized clinical trials. Pharmacoepidemiol Drug Saf (2003) 1.42
Could we – should we – calculate a risk exposure score for an HIV-negative individual in a serodiscordant couple? AIDS (2011) 1.41
The XVI International Conference on AIDS: the place to be! Retrovirology (2006) 1.39
Resistance to HIV integrase inhibitors. Curr Opin HIV AIDS (2012) 1.35
Tetherin restricts direct cell-to-cell infection of HIV-1. Retrovirology (2010) 1.34
Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection. PLoS Med (2006) 1.34
Arginine methylation of the human immunodeficiency virus type 1 Tat protein by PRMT6 negatively affects Tat Interactions with both cyclin T1 and the Tat transactivation region. J Virol (2007) 1.31
Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J Infect Dis (2009) 1.30
Chemoprophylaxis of HIV infection: moving forward with caution. J Infect Dis (2006) 1.28
Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev (2008) 1.27
Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategy. J Int Assoc Physicians AIDS Care (Chic) (2003) 1.27
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob Agents Chemother (2006) 1.25
Role of RNA in facilitating Gag/Gag-Pol interaction. J Virol (2002) 1.25
Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations. AIDS (2007) 1.24
Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Virol (2002) 1.23
The role of unintegrated DNA in HIV infection. Retrovirology (2011) 1.23
Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator. Virology (2002) 1.22
Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase. Antimicrob Agents Chemother (2013) 1.21
Mutation of the SP1 sequence impairs both multimerization and membrane-binding activities of human immunodeficiency virus type 1 Gag. J Virol (2005) 1.21
Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS (2014) 1.19
Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr (2004) 1.19
Cellular and molecular mechanisms involved in the establishment of HIV-1 latency. Retrovirology (2013) 1.18
Antiretroviral therapy : optimal sequencing of therapy to avoid resistance. Drugs (2008) 1.17
Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother (2009) 1.17
Long-term effectiveness of varicella vaccine: a 14-Year, prospective cohort study. Pediatrics (2013) 1.17
Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrob Agents Chemother (2009) 1.15
Evolution of HIV integrase resistance mutations. Curr Opin Infect Dis (2013) 1.13
Sequences downstream of the 5' splice donor site are required for both packaging and dimerization of human immunodeficiency virus type 1 RNA. J Virol (2003) 1.13
Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain (2013) 1.13
Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients. Antivir Chem Chemother (2004) 1.12
HIV transmission and primary drug resistance. AIDS Rev (2006) 1.12
Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C. AIDS Res Hum Retroviruses (2003) 1.11
PRMT6 diminishes HIV-1 Rev binding to and export of viral RNA. Retrovirology (2006) 1.10
Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (2005) 1.10
Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions. AIDS (2013) 1.10
The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacol Rev (2012) 1.10
Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine. Antimicrob Agents Chemother (2007) 1.10
Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob Agents Chemother (2010) 1.08
Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance. Retrovirology (2009) 1.07
Novel therapeutic strategies targeting HIV integrase. BMC Med (2012) 1.06
Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives. Antiviral Res (2007) 1.06
Multiple choices for HIV therapy with integrase strand transfer inhibitors. Retrovirology (2012) 1.06
The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology (2015) 1.06
Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes. Retrovirology (2009) 1.05
Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen. Antimicrob Agents Chemother (2006) 1.05
Factors affecting template usage in the development of K65R resistance in subtype C variants of HIV type-1. Antivir Chem Chemother (2010) 1.04
Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal. AIDS (2004) 1.04
A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1. PLoS One (2011) 1.04
Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins. J Virol (2005) 1.03
In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine. Antimicrob Agents Chemother (2011) 1.03
HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays. AIDS (2010) 1.03
In vitro identification and characterization of an early complex linking HIV-1 genomic RNA recognition and Pr55Gag multimerization. J Biol Chem (2004) 1.02
Negative effect of the M184V mutation in HIV-1 reverse transcriptase on initiation of viral DNA synthesis. Virology (2003) 1.02
Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection. Antimicrob Agents Chemother (2009) 1.01
Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination. AIDS (2011) 1.01
Spliced human immunodeficiency virus type 1 RNA is reverse transcribed into cDNA within infected cells. AIDS Res Hum Retroviruses (2004) 1.00
Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrob Agents Chemother (2012) 1.00
Integrase strand transfer inhibitors in the management of HIV-positive individuals. Ann Med (2014) 0.99
Isolation of drug-resistant mutant HIV variants using tissue culture drug selection. Methods Mol Biol (2009) 0.99
Synchronized maternal-infant elevations of primate CSF CRF concentrations in response to variable foraging demand. CNS Spectr (2005) 0.99
Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitor. AIDS Res Hum Retroviruses (2002) 0.99
Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation. Antimicrob Agents Chemother (2003) 0.99
Biochemical mechanism of HIV-1 resistance to rilpivirine. J Biol Chem (2012) 0.99